Group items tagged

The Pharmacists' Defence Association (PDA) says the pharmacy regulator should maintain a two-year post qualification eligibility criteria, in addition to the qualitative measures being introduced which would be in the best interest of patient safety, before a pharmacist is allowed to commence an IP course. The association was responding to an announcement by the GPhC's move to scrap the two year requirement for Independent Prescribing (IP) course. "The PDA accepts that the qualitative approach could mean greater individual consideration of potential IP course candidates and the two-year measure could have sometimes been a blunt tool. However, the PDA is already seeing cases of patient harm and allegations around fitness to practice arising from IP," the association said. The association also said that it supports individual pharmacists with near misses, as well as actual incidents, giving the organisation possibly the most comprehensive understanding of risk. Frontline pharmacists also recognise these issues and in a survey of over 1,000 pharmacists undertaken by the PDA in late 2021, of those who had 2+ years' experience of practice and who were already independent prescribers, 90 per cent said the qualifying period should be two years or more.

The Pharmacist' Defence Association (PDA) has welcomed the General Pharmaceutical Council (GPhC) and the Pharmaceutical Society of Northern Ireland (PSNI)'s plan to ensure a more robust, fair and positive experience for trainees, provisionally registered and potential pharmacists who will be sitting the November 2022 assessment. "Many candidates at the latest (June 2022) assessment experienced significant delays, technical issues, inadequate invigilation, and disturbances in test centres around the UK as the newly appointed company BTL ran the high-stakes pharmacist examinations for the first time. The next online exam is due in November 2022 and the PDA welcome proposed improvements to be introduced before that sitting," said the association. For some, provisional registration was the accepted response from the GPhC, but for others, such as potential pharmacists who did not want the provisional role, those unable to find a suitable provisional post, or some that did not meet the criteria for provisional registration, they found themselves in financial difficulties through no fault of their own, having reasonably expected to have joined the register in the Summer.

The Pharmacists' Defence Association (PDA) Union says it will be reaching out to LloydsPharmacy soon over a better deal on salary increase after the majority of its members rejected a three per cent offer made by the company recently. Paul Day, director, PDA Union told Pharmacy Business: "The PDA Union will communicate the response of employed pharmacists to the company and seek further discussion to try and find an offer that will be acceptable to union members. "Both management and union representatives have a vested interest in working to find such a solution and that is the outcome we hope to achieve." After months of negotiation by the PDA Union, the company offered a three per cent increase in salaries from the 1.8 per cent in the earlier offer made by the company. "Through negotiation over last few months that was increased to 3.0 per cent, plus a long term incentive plan (LTIP). Though the LTIP potentially offers large bonuses, it isn't guaranteed. Therefore what we put to members was the confirmed offer of three per cent increase in salaries," said Paul.

The Pharmacists' Defence Association (PDA) has raised concern over the Health Education England (HEE)'s decision on cutting funding to independent prescribing training. The HEE has reportedly decided that no funding will be available to back-fill trainees undertaking the pharmacist independent prescribing (PIP) qualification, or for the supervision of trainees by DPPs and DMPs. The PDA noted that, whilst all successful trainee pharmacists will be entering the GPhC register as independent prescribers from 2026, the existing pharmacist workforce is reliant on opportunities to undertake prescriber training through release from their employment, and the ability to secure a Designated Medical Practitioner (DMP) or Designated Prescribing Practitioner (DPP) to support the 90 days of supervised practice required. The association said it has already heard examples of potential DMPs or DPPs requesting a significant fee from trainees before they will provide supervision, adding that meeting that request is not an option for many. "This latest decision threatens to undermine the availability of the large numbers of pharmacists seeing supervisors as more IP training becomes available," it said in a statement.

A judicial review claim launched by the British Medical Association (BMA) against the General Medical Council (GMC) has parallelly intensified Pharmacists' Defence Association's (PDA) scrutiny over the use of the term 'pharmacy professionals'. PDA has criticised the evolving definition of 'pharmacy professionals,' and the potential risks to patient safety amidst regulatory ambiguity as part of "a far wider agenda." Concerns stem from what the PDA perceives as a blurring of distinctions between pharmacists and pharmacy technicians as "attempted homogenisation" by bodies like the General Pharmaceutical Council (GPhC), NHS, and Royal Pharmaceutical Society (RPS). Raising similar issue as the BMA against the GMC over its use of 'medical professionals for doctors and Medical Associate Professions (MAPs), Mark Koizol, Chairman of the PDA has said:

The Pharmacists' Defence Association (PDA) has begun conciliation with 86 pharmacy companies to safeguard the interests of former LloydsPharmacy pharmacists. The Advisory, Conciliation and Arbitration Service (Acas), a government agency, serves as a mediator between companies and employees to resolve disputes. If the ongoing mediation prove unsuccessful, individual employees retain the option to file claims in the employment tribunal, the PDA has said. The ongoing dispute centres around employers potentially failing to conduct the required consultation under the Transfer of Undertakings (Protection of Employment) regulations (TUPE) with employees and their representatives during employee transfers, the PDA said. The TUPE legislation, known for its complexity and technical nature, applies when a section of the company, like a pharmacy sold as an asset using standard disposal, undergoes a transfer. According to NHS England's recent pharmaceutical list, LloydsPharmacy has either sold or shuttered 461 branches since September 2022. According to NHSE data, as of June 30, the pharmacy chain operates approximately 512 pharmacies in England. This positions it as the third-largest chain after Boots UK and Well Pharmacy.

The Pharmacists Defence Association (PDA) has welcomed the government's action of publishing 'AI Regulation White Paper' which will regulate the artificial intelligence (AI) system used in pharmacy on Wednesday (29 March). The Association had raised concerns about the risk of patient harm due to inappropriate use of so-called AI to include that seen in some of the pharmacy systems undertaking clinical checks. For some time, it has been receiving concerns from practicing pharmacists describing examples of the potentially detrimental impact of automation and online pharmacy provision on patient safety and pharmacy practice. As a result, it raised these concerns with regulators, Chief Pharmaceutical Officers, and parliamentarians in all four nations of the UK to urge action. It said: "This is required not only to protect patients, but also the frontline pharmacists who could be blamed for potential harm caused by inappropriate use of so called 'AI' systems implemented by their employer." The PDA therefore, welcomes the announcement from the UK government that they intend to strengthen regulation of such technology, empowering existing regulators to come up with tailored, context-specific approaches that suit the way AI is actually being used in their sectors; this will include pharmacy.

In a bid to bolster professional leadership within the pharmacy sector, the four government Chief Pharmaceutical Officers (CPhOs) have embarked on a significant initiative, forming the UK Pharmacy Professional Leadership Advisory Board (UKPPLAB). In a recent communication, all pharmacists and pharmacy technicians received confirmation of the board members selected by the CPhOs, alongside a note from the board's appointed chair, who was chosen collectively by the four CPhOs and reports directly to the CPhO for England. Over three years, the 21-member Board will implement recommendations from the UK Commission on Pharmacy Professional Leadership's report aimed to enhance professional fulfillment among pharmacists while simultaneously augmenting patient safety standards. This announcement also follows with the appointment of Sir Hugh Taylor as its Independent Chair and the appointment of Independent Expert Members who expressed his delight over the role's "potential to lead and support collaboration across the professions in the UK". However, the move has been met with cautious optimism from the Pharmacists' Defence Association (PDA), urging the new board to uphold transparency and openness to garner trust among pharmacists.

More than a third of pharmacists who participated in a survey said they have seen an increase in patients declining prescriptions due to the cost in the last 12 months. The survey was jointly conducted by the Pharmacists' Defence Association (PDA) and the Royal Pharmaceutical Society (RPS), extending their support for the Prescription Charges Coalition (PCC). Responding to the survey, 90 per cent of pharmacists admitted seeing cases where patients decline all the medicines on a prescription due to cost. Nearly all respondents said they have seen cases where patients declined some of their prescribed medicines and more than a quarter of them have experienced such situation often. They have warned of the impact of prescription charges as patients are denying vital medicines, including those for blood pressure and mental health, inhalers, antibiotics, pain relief, and statins, which can have potential consequences for the individual's health.

Pharmacy leaders have called for reassurance that the workforce plan, expected by April 2023, will cover the entirety of the pharmacy workforce across the health service, including in community pharmacies. A joint letter has been signed by representatives from 14 pharmacy organisations which highlights that with continued pressures on services, it is more important than ever to support the pharmacy workforce so that the staff needed to deliver patient care now and into the future can be recruited, trained and retained. Mark Koziol, Pharmacists' Defence Association (PDA) Chairman said: "Our pharmacist members practise across the entire health system and have the potential to do far more to help patients and improve public health, but they can only do so safely if they are in appropriately staffed workplaces. This is a workforce issue, so it is important that the Government works with representatives of the pharmacist workforce, and of their employers, to get a suitably agreed plan in place." Thorrun Govind, English Pharmacy Board Chair, Royal Pharmaceutical Society (RPS), said: "It will be crucial to use the skills of all our health professions to support the NHS recovery, reduce health inequalities, manage the growing cost of long-term conditions, and deliver best value from medicines.

In a surprising move that has divided the pharmacy profession, the General Pharmaceutical Council (GPhC) has sanctioned hundreds of pharmacies to allow patients to self-select certain Pharmacy (P) medicines, a decision met with strong opposition from the Royal Pharmaceutical Society (RPS) as well as from the Pharmacy Defense Association (PDA). In a statement, RPS shared that at a board meeting held on 19th June, they expressed "disappointment" over what they described as a lack of prior consultation and comprehensive communication from the GPhC regarding the implications of this policy shift. They argue that allowing patients to self-select certain P medicines could potentially jeopardize established professional guidelines and compromise the role of pharmacists in ensuring safe medication use. "Enabled by the General Pharmaceutical Council, we understand that hundreds of pharmacies, from large multiples to small independents, have been approved by the regulator to enable patients to self-select certain P medicines," the statement said.